Immune parameters relevant to neural xenograft survival in the primate brain

Xenotransplantation

Volumn 10, Issue 1, 2003, Pages 41-49

  Cicchetti, Francesca ^a,d   Fodor, W ^b   Deacon, T W ^a   Van Horne, C ^a,c   Rollins, S ^b   Burton, W ^b   Costantini, L C ^a   Isacson, O ^a  

^a MCLEAN HOSPITAL   (United States)

^b ALEXION PHARMACEUTICALS   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d LAVAL UNIVERSITY   (Canada)

Author keywords

Dopamine; Immune response; Neurodegenerative disorder; Striatum; Xenotransplantation

Indexed keywords

AZATHIOPRINE; CD59 ANTIGEN; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5 ANTIBODY; CYCLOSPORIN A; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; FUCOSYLTRANSFERASE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; BRAIN TISSUE; CELL DEATH; CLINICAL PROTOCOL; COMPLEMENT ACTIVATION; CONFERENCE PAPER; CONTROLLED STUDY; CORPUS STRIATUM; CYTOLYSIS; DEGENERATIVE DISEASE; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOLOGY; MONKEY; NERVE GRAFT; NONHUMAN; PARKINSON DISEASE; PRIMATE; PRIORITY JOURNAL; SWINE; XENOGRAFT; ANIMAL; ARTICLE; BLOOD; BRAIN TRANSPLANTATION; FETAL TISSUE TRANSPLANTATION; GENETICS; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; MACACA; PARKINSONISM; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD59; BRAIN TISSUE TRANSPLANTATION; COMPLEMENT ACTIVATION; COMPLEMENT C5; FETAL TISSUE TRANSPLANTATION; FUCOSYLTRANSFERASES; GRAFT SURVIVAL; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOSUPPRESSION; MACACA FASCICULARIS; MACACA MULATTA; PARKINSONIAN DISORDERS; SWINE; TRANSPLANTATION, HETEROLOGOUS;

EID: 0038791992     PISSN: 0908665X     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3089.2003.01130.x     Document Type: Conference Paper

References (42)

1. ISACSON O, COSTANTINI LC, SCHUMACHER JM. Cell implantation therapies for Parkinson's disease using neural stem, transgenic or xenogeneic donor cells. In: CALNE D, DEUTCH A, eds. Parkinsonism and Related Disorders. Amsterdam: Elsevier Science Ltd, 2001: 205.
2. PICCINI P, BROOKS DJ, BJORKLUND A. et al. Dopamine release from nigral transplants visualized in vivo in Parkinson's patient. Nat Neurosci 1999; 2: 1137.
3. PICCINI P, LINDVALL O, BJORKLUND A. et al. Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Ann Neurol 2000; 48: 689.
4. DEACON TW, SCHUMACHER JM, DINSMORE J. et al. Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease. Nat Med 1997; 3: 350.
5. GALPERN WG, BURNS LH, DEACON TW. et al. Xenotransplantation of porcine fetal ventral mesencephalon in a rat model of Parkinson's disease: functional recovery and graft morphology. Exp Neurol 1996; 140: 1.
6. HUFFAKER TK, BOSS BD, MORGAN AS. et al. Xenografting of fetal pig ventral mesencephalon corrects motor asymmetry in the rat model of Parkinson's disease. Brain Res 1989; 77: 329.
7. ISACSON O, DEACON TW, PAKZABAN P. et al. Transplanted xenogeneic neural cells in neurodegenerative disease models exhibit remarkable axonal target specificity and distinct growth patterns of glial and axonal fibres. Nat Med 1995; 1: 1189.
8. KOPYOV OV, JACQUES DB, RAND RW. et al. Fetal human and pig mesencephalon xenografts have equal effectiveness in behavioral restoration of damaged rat brain. Transplant Proc 1992; 24: 547.
9. PAKZABAN P, ISACSON O. Neural xenotransplantation. reconstruction of neuronal circuitry across species barriers. Neuroscience 1994; 62: 989.
10. BARKER RA, RATCLIFFE E, McLAUGHLIN M. et al. A role for complement in the rejection of porcine ventral mesencephalic xenografts in a rat model of Parkinson's disease. J Neurosci 2000; 20: 3415.
11. SCHUMACHER JM, ELLIAS SA, PALMER EP. et al. Transplantation of embryonic porcine mesencephalic tissue in patients with PD. Neurology 2000; 54: 1042.
12. AUCHINCLOSS HJ, SACHS D. Xenogeneic transplantation. Annu Rev Immunol 1998; 16: 433.
13. WANG H, ROLLINS SA, GAO Z. et al. Complement inhibition with an anti-C5 monoclonal antibody prevents hyperacute rejection in a xenograft heart transplantation model, Transplantation 1999; 68: 1643.
14. DALMASSO AP, VERCELLOTTI GM, FISCHEL RJ. et al. Mechanism of complement activation in the hyperacute rejection of porcine organs transplanted into primate recipients. Am J Pathol 1992; 140: 1157.
15. KENNEDY SP, ROLLINS SA, BURTON WV. et al. Protection of porcine aortic endothelial cells from complement-mediated cell lysis and activation by recombinant human CD59. Transplantation 1994; 57: 1494.
16. MCCURRY KR, KOOYMAN DL, ALVARADO CG. et al. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nat Med 1995; 1: 423.
17. FODOR WL, WILLIAMS BL, MATIS LA. et al. Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection. Proc Natl Acad Sci USA 1994; 91: 111537.
18. HANTRAYE P, RICHE D, MAZIERE M, ISACSON O. Intrastriatal transplantation of cross-species fetal striatal cells reduces abnormal movements in a primate model of Huntington disease. Proc Natl Acad Sci USA 1992; 89: 4187.
19. WÜLLNER U, PAKZABAN P, HANTRAYE P. et al. Dopaminc terminal loss and onset of motor symptoms in MPTP-treated monkeys: a positron emission tomography study with 11C-CFT. Exp Neurol 1994; 126: 1.
20. BURNS LH, PAKZABAN P, DEACON TW. et al. Selective putaminal excitotoxic lesions in non-human primates model the movement disorder of Huntington disease. Neuroscience 1994; 64: 1007.
21. ISACSON O, DEACON TW. Specific axon guidance factors persist in the adult brain as demonstrated by pig neuroblasts transplanted to the rat. Neuroscience 1996; 75: 827.
22. RINDER CS, RINDER HM, SMITH BR. et al. Blockade of C5a and C5b-9 generation inhibits leukocyte ad platelet activation during extracorporeal circulation. J Clin Invest 1995; 96: 1564.
23. THOMAS TC, ROLLINS SA, ROTHER RP. et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol 1996; 33: 1389.
24. VAKEVA AP, AGAH A, ROLLINS SA. et al. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 1998; 97: 2259.
25. LINDVALL O, SAWLE G, WIDNER H. et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann Neurol 1994; 35: 172.
26. FREED CR, BREEZE RE, SCHNECK SA. Transplantation of fetal mesencephalic tissue in Parkinson's disease. N Engl J Med 1995; 333: 730.
27. KORDOWER JH, FREEMAN TB, SNOW BJ. et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 1995; 332: 1118.
28. BOWMAN JS, 3RD, ANGSTADT JD, WAYMACK JP, JAFFERS GJ. A comparison of triple-therapy with double-therapy immunosuppression in cadaveric renal transplantation. Transplantation 1992; 53: 556.
29. TARANTINO A, AROLDI A, STUCCHI L. et al. A randomized prospective trial comparing cyclosporine monotherapy with triple-drug therapy in renal transplantation. Transplantation 1991; 52: 53.
30. BRUNDIN P, WIDNER H, NILSSON OG. et al. Intracerebral xenografts of dopamine neurons: the role of immunosuppression and the blood-brain barrier. Exp Brain Res 1989; 75: 95.
31. ISACSON O, PAKZABAN P, GALPERN WR. Transplanting fetal neural xenogeneic cells in Parkinson's and Huntington's disease models. In: FREEMAN, T, WIDNER, H, eds. Cell Transplantation for Neurological Disorders. Totowa, NJ: Humana Press, 1998: 189.
32. SUMITRAN S, LIU J, CZECH KA. et al. Human natural antibodies cytotoxic to pig embryonic brain cells recognize novel non-Ga1 alpha1,3Ga1-based xenoantigens. Exp Neurol 1999; 159: 347.
33. SANDRIN MS, FODOR WL, MOUHTOURIS E. et al. Enzymatic remodelling of the carbohydrate surface of a xenogenic cell substantially reduces human antibody binding and complement-mediated cytolysis. Nat Med 1995; 1: 1248.
34. COSTA C, ZHAO L, BURTON W. et al. Expression of the human alpha1,2-fucosyltransferase in transgenic pigs modifies the cell surface carbohydrate phenotype and confers resistance to human serum-mediated cytolysis. FASEB J 1999; 13: 1762.
35. KROSHUS T, ROLLINS SA, DALMASSO AP. et al. Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation. Transplantation 1995; 60: 1194.
36. KLEE GC. Human anti-mouse antibodies. Arch Pathol Laboratory Med 2000; 124: 921.
37. REGAN J, CAMPBELL K, SMITH L. et al. Characterization of anti-Thymoglobulin, anti-Atgam and anti-OKT3 IgG antibodies in human serum with an 11-min ELISA. Transpl Immunol 1997; 5: 49.
38. DONATSCH P, RYFFEL B. Pharmacokinetics of cyclosporine in toxicological studies. Transpl Proc 1986; 18: 71.
39. HAUSEN B, IKONEN T, BRIFFA N. et al. Combined immunosuppression with cyclosporine (neoral) and SDZ RAD in non-human primate lung transplantation: systemic pharmacokinetic-based trials to improve efficacy and tolerability. Transplantation 2000; 69: 76.
40. IKONEN TS, GUMMERT JF, SERKOVA N. et al. Efficacies of sirolimus (rapamycin) and cyclosporinc in allograft vascular disease in non-human primates: trough levels of sirolimus correlate with inhibition of progression of arterial intimal thickening. Transpl Int 2000; 13: S314.
41. SCHUURMAN HJ, RINGERS J, SCHULER W. et al. Oral efficacy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney allotransplantation. Transplantation 2000; 69: 737.
42. ARMSTRONG RJ, HARROWER TP, HURELBRINK CB. et al. Porcine neural xenografts in the immunocompetent rat: immune response following grafting of expanded neural precursor cells. Neuroscience 2001; 106: 201.